Enterprise Value

48.89M

Cash

29.6M

Avg Qtr Burn

-7.022M

Short % of Float

1.19%

Insider Ownership

3.90%

Institutional Own.

1.92%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 3

Initiation

Phase 2

Data readout

Pelareorep + Retifanlimab Details
Breast cancer, Triple-negative breast cancer

Phase 2

Update

Pelareorep + Atezolizumab (Tecentriq) Details
Gastric cancer, Colorectal cancer , Cancer, Pancreatic cancer, Squamous cell carcinoma of the anal canal

Phase 1/2

Data readout

Phase 1/2

Update

Phase 1/2

Initiation

Pelareorep + Keytruda® Details
Pancreatic cancer, Sarcoma

Failed

Discontinued